288 related articles for article (PubMed ID: 31427714)
1. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
Horvath A; Rainer F; Bashir M; Leber B; Schmerboeck B; Klymiuk I; Groselj-Strele A; Durdevic M; Freedberg DE; Abrams JA; Fickert P; Stiegler P; Stadlbauer V
Sci Rep; 2019 Aug; 9(1):12000. PubMed ID: 31427714
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice.
Takashima S; Tanaka F; Kawaguchi Y; Usui Y; Fujimoto K; Nadatani Y; Otani K; Hosomi S; Nagami Y; Kamata N; Taira K; Tanigawa T; Watanabe T; Imoto S; Uematsu S; Fujiwara Y
Neurogastroenterol Motil; 2020 Jul; 32(7):e13841. PubMed ID: 32319196
[TBL] [Abstract][Full Text] [Related]
3. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
Macke L; Schulz C; Koletzko L; Malfertheiner P
Aliment Pharmacol Ther; 2020 Mar; 51(5):505-526. PubMed ID: 31990420
[TBL] [Abstract][Full Text] [Related]
4. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use.
Naito Y; Kashiwagi K; Takagi T; Andoh A; Inoue R
Digestion; 2018; 97(2):195-204. PubMed ID: 29316555
[TBL] [Abstract][Full Text] [Related]
5. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors.
Hojo M; Asahara T; Nagahara A; Takeda T; Matsumoto K; Ueyama H; Matsumoto K; Asaoka D; Takahashi T; Nomoto K; Yamashiro Y; Watanabe S
Dig Dis Sci; 2018 Nov; 63(11):2940-2949. PubMed ID: 29796911
[TBL] [Abstract][Full Text] [Related]
6. Influence of proton pump inhibitors on microbiota in chronic liver disease patients.
Yamamoto K; Ishigami M; Honda T; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Hayashi K; Goto H; Hirooka Y
Hepatol Int; 2019 Mar; 13(2):234-244. PubMed ID: 30737678
[TBL] [Abstract][Full Text] [Related]
7. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study.
Horvath A; Leber B; Feldbacher N; Steinwender M; Komarova I; Rainer F; Blesl A; Stadlbauer V
Sci Rep; 2020 Feb; 10(1):2723. PubMed ID: 32066847
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
[TBL] [Abstract][Full Text] [Related]
9. Oral microbiome alterations of healthy volunteers with proton pump inhibitor.
Mishiro T; Oka K; Kuroki Y; Takahashi M; Tatsumi K; Saitoh T; Tobita H; Ishimura N; Sato S; Ishihara S; Sekine J; Wada K; Kinoshita Y
J Gastroenterol Hepatol; 2018 May; 33(5):1059-1066. PubMed ID: 29105152
[TBL] [Abstract][Full Text] [Related]
10. Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis.
Lachar J; Bajaj JS
Semin Liver Dis; 2016 Sep; 36(4):327-330. PubMed ID: 27997972
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
[TBL] [Abstract][Full Text] [Related]
12. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.
Shaw KA; Bertha M; Hofmekler T; Chopra P; Vatanen T; Srivatsa A; Prince J; Kumar A; Sauer C; Zwick ME; Satten GA; Kostic AD; Mulle JG; Xavier RJ; Kugathasan S
Genome Med; 2016 Jul; 8(1):75. PubMed ID: 27412252
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis.
Dultz G; Piiper A; Zeuzem S; Kronenberger B; Waidmann O
Aliment Pharmacol Ther; 2015 Mar; 41(5):459-66. PubMed ID: 25523381
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.
Bajaj JS; Acharya C; Fagan A; White MB; Gavis E; Heuman DM; Hylemon PB; Fuchs M; Puri P; Schubert ML; Sanyal AJ; Sterling RK; Stravitz TR; Siddiqui MS; Luketic V; Lee H; Sikaroodi M; Gillevet PM
Am J Gastroenterol; 2018 Aug; 113(8):1177-1186. PubMed ID: 29872220
[TBL] [Abstract][Full Text] [Related]
15. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome.
Sung CM; Lin YF; Chen KF; Ke HM; Huang HY; Gong YN; Tsai WS; You JF; Lu MJ; Cheng HT; Lin CY; Kuo CJ; Tsai IJ; Hsieh SY
Cell Mol Gastroenterol Hepatol; 2019; 8(2):301-318.e2. PubMed ID: 31004827
[TBL] [Abstract][Full Text] [Related]
16. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
Bajaj JS; Cox IJ; Betrapally NS; Heuman DM; Schubert ML; Ratneswaran M; Hylemon PB; White MB; Daita K; Noble NA; Sikaroodi M; Williams R; Crossey MM; Taylor-Robinson SD; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G951-7. PubMed ID: 25258407
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified.
Bruno G; Zaccari P; Rocco G; Scalese G; Panetta C; Porowska B; Pontone S; Severi C
World J Gastroenterol; 2019 Jun; 25(22):2706-2719. PubMed ID: 31235994
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis.
Tergast TL; Wranke A; Laser H; Gerbel S; Manns MP; Cornberg M; Maasoumy B
Liver Int; 2018 Sep; 38(9):1602-1613. PubMed ID: 29675988
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies.
Wu X; Zhang D; Yu Y; Lou L; Li X
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32406491
[TBL] [Abstract][Full Text] [Related]
20. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
Wellhöner F; Döscher N; Tergast TL; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Maasoumy B; Wedemeyer H; Cornberg M; Pieper DH; Heidrich B
Scand J Gastroenterol; 2019 Aug; 54(8):1033-1041. PubMed ID: 31361979
[No Abstract] [Full Text] [Related]
[Next] [New Search]
